[Nivolumab (NSCLC) - Addendum to Commission A20-118]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003887
German
Original Title:
Nivolumab (NSCLC) - Addendum zum Auftrag A20-118
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a21-57.html
Year Published:
2021
URL for published report:
https://www.iqwig.de/download/a21-57_nivolumab_addendum-zum-auftrag-a20-118_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Nivolumab
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Antibodies, Monoclonal, Humanized
Keywords
- Nivolumab
- Ipilimumab
- Nutzenbewertung
- NCT03215706
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.